Japan reimburses diagnostic medical devices under the NHI system, based on evaluations by MHLW & Chuikyo. Devices must demonstrate clinical accuracy, safety, cost-effectiveness, & healthcare utility. Reimbursement is determined through classification, pricing comparisons, or cost-based methods. Innovative diagnostics may receive premium pricing if they significantly enhance patient outcomes or healthcare efficiency.
